Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Pancreatic Cancer Cells Vulnerable to Glutamine Pathway Inhibitors

By BiotechDaily International staff writers
Posted on 10 Apr 2013
Pancreatic cancer cells utilize the amino acid glutamine to fuel their metabolism and are dependent on a single molecular pathway that may be susceptible to pharmaceutical inhibition.

Investigators at the Dana-Farber Cancer Institute (Boston, MA, USA) reported in the March 27, 2013, online edition of the journal Nature that they had identified a noncanonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that was required for tumor growth. While most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into alpha-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle (Kreb's cycle), PDAC was shown to rely on a distinct pathway in which glutamine-derived aspartate was transported into the cytoplasm where it was converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate was converted into malate and then pyruvate, increasing the NADPH/NADP+ ratio, which could then maintain the cellular redox state.

PDAC cells were strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway led to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions resulted in a pronounced suppression of PDAC growth in vitro and in vivo.

Reprogramming of glutamine metabolism by PDAC was found to be mediated by the KRAS oncogene. The protein product of the normal KRAS (Kirsten rat sarcoma viral oncogene) gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.

“Pancreatic cancer cells have painted themselves into a metabolic bottleneck,” said senior author Dr. Alec Kimmelman, assistant professor of radiation oncology at the Dana-Farber Cancer Institute. “If you suppress any enzyme in that pathway, the cancer cells cannot effectively compensate and they can no longer grow. We do not have a drug to do this in humans, but we are working on inhibitors of enzymes in the glutamine pathway.”

Related Links:

Dana-Farber Cancer Institute



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: A mouse mammary gland missing the tumor-suppressor p53 shows expression of ARF (green), now known for a backup role in protecting cells from becoming cancerous. If both p53 and ARF are mutated, the tumors that form are aggressive and may benefit from treatment with anti-inflammatory drugs called JAK inhibitors, currently prescribed for rheumatoid arthritis (Photo courtesy of Raleigh Kladney).

Anti-Inflammatory Drugs May Treat Some Aggressive Rumors

New research raises the possibility that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. By studying triple-negative... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.